Flunazol 50 mg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Fluconazole |
| Company | Pharmadesh laboratories ltd |
| Also available as |
Indications
- Vaginal Candidiasis
- Oropharyngeal Candidiasis
- Oesophageal Candidiasis
- Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
- Kerion
- Pityriasis versicolor
- Onychomycosis
- Invasive candidal infections and cryptococcal infections (including meningitis)
- Prevention of cryptococcal meningitis
- Prevention of fungal infections in immunocompromised patients
- Systemic Candidiasis and Cryptococcal infection
- Superficial Candidiasis
- Fungal urinary tract infections
- Disseminated candidiasis
- Prophylaxis for fungal infection in neutropenic cancer patients
- Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis
Pharmacology
Potent inhibitor of fungal cytochrome P-450 dependent enzymes
Dosage & Administration
- 150 mg as a single dose for Vaginal Candidiasis
- 200 mg in 1st day followed by 100 mg daily for 14 days for Oropharyngeal Candidiasis
- 200 mg in 1st day followed by 100 mg daily for 14-30 days for Oesophageal Candidiasis
- 150 mg weekly for 4-6 weeks for Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
- 50 mg daily for 20 days for Kerion
- 400 mg as a single dose for Pityriasis versicolor
- 150 mg weekly for 12 months for Onychomycosis
- Orally or by IV infusion, 400 mg on first day then 200-400 mg daily for Invasive candidal infections and cryptococcal infections (including meningitis)
Interaction
Increased prothrombin time after warfarin administration, prolonged serum half-life of concomitantly administered oral sulphonyl ureas, increased plasma concentrations of fluconazole by 40% with co-administration of hydrochlorothiazide, potential increase in phenytoin levels, decreased AUC and shorter half-life of fluconazole with co-administration of rifampicin
Contraindications
Known hypersensitivity to Fluconazole or related triazole compounds
Side Effects
- Nausea
- Abdominal discomfort
- Diarrhoea
- Flatulence
- Rash (Incidence less than 1%)
- Anaphylaxis in rare cases
Pregnancy & Lactation
Adverse fetal effects seen in animals at high dose levels associated with maternal toxicity, not recommended in pregnancy or in women of childbearing potential unless adequate contraception is employed
Precautions & Warnings
- Abnormalities of hepatic, renal, haematological and other biochemical function tests
- Rare occurrence of hepatic necrosis
- Rare development of exfoliative cutaneous reactions such as Stevens Johnson Syndrome and toxic epidermal necrolysis
- Not recommended for use in nursing mothers
- Unlikely to impair a patient's ability to drive or use machinery
Use in Special Populations
- Normal dose for the elderly if no evidence of renal impairment
- Excreted predominantly in urine, no adjustments in single dose therapy required for renal impairment
- Possible dosage interval and daily dosage adjustments based on creatinine clearance for renal impairment
Overdose Effects
Supportive measures and symptomatic treatment, forced volume diuresis may increase elimination rate, haemodialysis may decrease plasma levels by approximately 50%
Therapeutic Class
Drugs for subcutaneous and mycoses
Storage Conditions
Dry place away from light and heat, keep out of the reach of children